Related Experiment Videos

Fungal endocarditis, 1995-2000

Lígia C Pierrotti1, Larry M Baddour

  • 1Hospital das Clinicas, University de São Paulo, São Paulo, Brazil.

Chest
|July 13, 2002
PubMed

Insights

Fungal endocarditis (FE) cases show a shift in risk factors, with cardiac abnormalities and prosthetic valves more common than injection drug use. High mortality rates, especially for Aspergillus-related FE, highlight the need for new treatment strategies.

Area of Science:

  • Infectious Diseases
  • Cardiology
  • Mycology

Background:

  • Fungal endocarditis (FE) is a serious infection affecting heart valves.
  • The epidemiology and risk factors for FE have been evolving.
  • Previous studies may not fully capture current trends in FE.

Purpose of the Study:

  • To analyze the characteristics and outcomes of fungal endocarditis cases.
  • To identify the changing risk factors and predisposing conditions for FE.
  • To assess the current mortality rates associated with FE.

Main Methods:

  • Systematic review of English-language literature.
  • Inclusion of cases diagnosed between January 1, 1995, and June 30, 2000.
  • Data extraction on patient demographics, risk factors, and outcomes.

Main Results:

  • 152 cases of fungal endocarditis were identified.
  • The median patient age was 44 years.
  • Key risk factors included underlying cardiac abnormalities (47.3%), prosthetic valves (44.6%), and central venous catheters (30.4%).
  • Injection drug use was a risk factor in only 4.1% of cases.
  • Mortality rates remain high, particularly for Aspergillus-related FE.

Conclusions:

  • Fungal endocarditis epidemiology has shifted, with non-injection drug use related factors becoming more prevalent.
  • Underlying cardiac conditions and medical devices are significant predisposing factors.
  • Improved and novel therapeutic approaches are crucial to reduce the high mortality associated with fungal endocarditis.

Related Concept Videos